Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

NCT04164901 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

331

Enrollment

OTHER

Sponsor class

Conditions

Grade 2 Glioma
Residual Glioma
Recurrent Glioma

Interventions

DRUG: Vorasidenib
DRUG: Matching Placebo

Sponsor

Institut de Recherches Internationales Servier